Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies.
Nakashima K, Umeda Y, Demura Y, Sonoda T, Tada T, Yamaguchi M, Anzai M, Kadowaki M, Oi M, Honjo C, Mitsui M, Waseda Y, Ishizuka T. Nakashima K, et al. Among authors: umeda y. Oncology. 2024 Jan 30:1-11. doi: 10.1159/000535994. Online ahead of print. Oncology. 2024. PMID: 38290482
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer.
Anzai M, Morikawa M, Okuno T, Umeda Y, Demura Y, Sonoda T, Yamaguchi M, Kanno K, Shiozaki K, Ameshima S, Akai M, Ishizuka T. Anzai M, et al. Among authors: umeda y. Medicine (Baltimore). 2017 Dec;96(51):e9320. doi: 10.1097/MD.0000000000009320. Medicine (Baltimore). 2017. PMID: 29390506 Free PMC article. Clinical Trial.
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.
Sonoda T, Umeda Y, Demura Y, Tada T, Nakashima K, Anzai M, Yamaguchi M, Shimada A, Ohi M, Honjo C, Waseda Y, Akai M, Ishizuka T. Sonoda T, et al. Among authors: umeda y. Cancer Med. 2023 Jun;12(12):13041-13053. doi: 10.1002/cam4.5978. Epub 2023 Apr 20. Cancer Med. 2023. PMID: 37081729 Free PMC article. Clinical Trial.
Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.
Negoro Y, Yano R, Yoshimura M, Suehiro Y, Yamashita S, Kodawara T, Watanabe K, Tsukamoto H, Nakamura T, Kadowaki M, Morikawa M, Umeda Y, Anzai M, Ishizuka T, Goto N. Negoro Y, et al. Among authors: umeda y. Int J Clin Oncol. 2019 Mar;24(3):256-261. doi: 10.1007/s10147-018-1358-4. Epub 2018 Oct 17. Int J Clin Oncol. 2019. PMID: 30328531
Safety and utility of Endoscopic Ultrasound with Bronchoscope-guided Fine Needle Aspiration (EUS-B-FNA) in suspected lung cancer patients with poor respiratory or general conditions: a prospective three-center observational study.
Nakashima K, Umeda Y, Demura Y, Takeda T, Tada T, Sato M, Jikuya N, Kurokawa K, Sonoda T, Yamaguchi M, Mitsui M, Oi M, Chikazawa R, Waseda Y, Anzai M, Akai M, Ishizuka T. Nakashima K, et al. Among authors: umeda y. BMC Pulm Med. 2023 Jun 14;23(1):206. doi: 10.1186/s12890-023-02508-2. BMC Pulm Med. 2023. PMID: 37316839 Free PMC article.
Successful treatment with lenvatinib in a patient with thymic carcinoma presenting with cardiac tamponade: a case report and review of literature.
Nakashima K, Azuma T, Ohta R, Fujii Y, Sato M, Igarashi K, Kadowaki M, Umeda Y, Waseda Y, Anzai M, Kobayashi M, Ishizuka T. Nakashima K, et al. Among authors: umeda y. Anticancer Drugs. 2022 Sep 1;33(8):761-764. doi: 10.1097/CAD.0000000000001332. Epub 2022 Aug 10. Anticancer Drugs. 2022. PMID: 35946531 Review.
710 results